Aspire Financial Statements From 2010 to 2026

ASBP Stock   1.46  0.14  10.61%   
Analyzing historical trends in various income statement and balance sheet accounts from Aspire BioPharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aspire BioPharma's valuation are summarized below:
Gross Profit
884
Market Capitalization
7.4 M
Enterprise Value Revenue
7.4 K
Revenue
1.9 K
Earnings Share
(24.46)
There are currently ninety-seven fundamental signals for Aspire BioPharma that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Aspire BioPharma's prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction.
Check Aspire BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aspire BioPharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Selling General Administrative of 3.7 M or Other Operating Expenses of 3.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Aspire financial statements analysis is a perfect complement when working with Aspire BioPharma Valuation or Volatility modules.
  
Build AI portfolio with Aspire Stock
Check out the analysis of Aspire BioPharma Correlation against competitors.
To learn how to invest in Aspire Stock, please use our How to Invest in Aspire BioPharma guide.

Aspire BioPharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets126.5 K133.2 K19.1 M
Pretty Stable
Short and Long Term Debt Total1.5 M1.5 M421 K
Slightly volatile
Other Current Liabilities137.3 K127.7 K80.4 K
Slightly volatile
Total Current LiabilitiesM1.9 M582.3 K
Slightly volatile
Accounts Payable374.6 K356.8 K81 K
Slightly volatile
Non Current Assets Total5.7 MM20.1 M
Pretty Stable
Common Stock Shares Outstanding52.3 M29.7 M36.4 M
Slightly volatile
Liabilities And Stockholders Equity126.5 K133.2 K19.1 M
Pretty Stable
Other Current Assets92.2 K97.1 K263.9 K
Slightly volatile
Other Stockholder Equity1.3 M1.4 M938.5 K
Slightly volatile
Total Liabilities2.7 M1.5 M1.2 M
Slightly volatile
Total Current Assets126.5 K133.2 K300.3 K
Very volatile
Short Term Debt1.5 M1.5 M421 K
Slightly volatile
Common Stock145.3 K153 K18.8 M
Pretty Stable
Current Deferred Revenue64.1472.1578.7553
Slightly volatile
Cash3.1 K3.3 K381.5 K
Slightly volatile
Cash And Short Term Investments3.1 K3.3 K381.5 K
Slightly volatile
Short and Long Term Debt1.5 M1.5 M292.8 K
Slightly volatile
Capital Stock18.8 K19.8 K186 K
Slightly volatile
Non Current Liabilities Other3.1 M3.5 M3.8 M
Slightly volatile
Net Receivables29.2 K32.9 K35.9 K
Slightly volatile

Aspire BioPharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.6 M1.5 M441.9 K
Slightly volatile
Selling General Administrative3.7 M3.6 M766 K
Slightly volatile
Other Operating Expenses3.7 M3.6 M764.3 K
Slightly volatile
Total Operating Expenses3.7 M3.6 M764.3 K
Slightly volatile
Tax Provision443433587
Slightly volatile
Selling And Marketing Expenses77.4 K145 K57.6 K
Slightly volatile
Research Development104.5 K129.9 K160.6 K
Slightly volatile
Income Tax Expense7771.2 K681
Slightly volatile
Interest Income469.1 K493.8 K4.9 M
Slightly volatile

Aspire BioPharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow3.1 K3.3 K161.4 K
Slightly volatile
Begin Period Cash Flow9.6 K10.1 K172.9 K
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables102.7 K149.7 K103.6 K
Slightly volatile
Cash Per Share1.0E-41.0E-40.003
Slightly volatile
ROE17.059.3639.9041
Slightly volatile
Current Ratio0.09580.10.9461
Pretty Stable
Average Receivables14.6 K16.4 K17.9 K
Slightly volatile
Interest Debt Per Share0.01070.01020.0087
Pretty Stable
Debt To Assets8.097.72.0068
Slightly volatile
Graham Number0.960.661.0526
Slightly volatile
Quick Ratio0.09580.10.9461
Pretty Stable
Cash Ratio0.00240.00251.2542
Slightly volatile
Debt Ratio8.097.72.0068
Slightly volatile
Return On Equity17.059.3639.9041
Slightly volatile

Aspire Fundamental Market Drivers

About Aspire BioPharma Financial Statements

Aspire BioPharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aspire BioPharma investors may analyze each financial statement separately, they are all interrelated. The changes in Aspire BioPharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Aspire BioPharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue 72.15  64.14 

Pair Trading with Aspire BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aspire BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aspire BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Aspire Stock

  0.75DD Dupont De Nemours Earnings Call This WeekPairCorr
  0.74JNJ Johnson JohnsonPairCorr
  0.74PFE Pfizer Inc Aggressive PushPairCorr
  0.73MRK Merck Company Aggressive PushPairCorr
  0.63NVR NVR IncPairCorr
The ability to find closely correlated positions to Aspire BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aspire BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aspire BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aspire BioPharma to buy it.
The correlation of Aspire BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aspire BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aspire BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aspire BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Aspire Stock Analysis

When running Aspire BioPharma's price analysis, check to measure Aspire BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aspire BioPharma is operating at the current time. Most of Aspire BioPharma's value examination focuses on studying past and present price action to predict the probability of Aspire BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aspire BioPharma's price. Additionally, you may evaluate how the addition of Aspire BioPharma to your portfolios can decrease your overall portfolio volatility.